Patents by Inventor Terri Sebree

Terri Sebree has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20240122873
    Abstract: The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
    Type: Application
    Filed: October 9, 2023
    Publication date: April 18, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: James Griesser, Thomas W. Dobbins, Terri Sebree
  • Cannabidiol for the Treatment of Refractory Seizures
    Publication number: 20240009210
    Abstract: Provided are methods of treating refractory seizures in a human subject, e.g., a child, that include administering an effective amount of cannabidiol (CBD), e.g., in a transdermal gel.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 11, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Donna Gutterman, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230414533
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20230364028
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: March 21, 2023
    Publication date: November 16, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11779549
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 10, 2023
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230059709
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD). Specifically, subjects having moderate to severe ASD and relatively high social avoidance and/or anxiety are more likely to show a reduction in irritability when treated with CBD.
    Type: Application
    Filed: October 20, 2022
    Publication date: February 23, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Stephen V. O'Quinn, Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230024756
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.
    Type: Application
    Filed: September 30, 2022
    Publication date: January 26, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230000793
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 5, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230000790
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 5, 2023
    Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230000792
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 5, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • Treatment of 22Q11.2 deletion syndrome with cannabidiol
    Patent number: 11458109
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11458110
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
    Publication number: 20220218625
    Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 14, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman, John Messenheimer
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20220096396
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 31, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20210401769
    Abstract: The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: James Griesser, Thomas W. Dobbins, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL
    Publication number: 20210369643
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20210077421
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 18, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS
    Publication number: 20210030665
    Abstract: The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
    Type: Application
    Filed: August 18, 2020
    Publication date: February 4, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Donna Gutterman, Terri Sebree, Ted Smith, John Messenheimer
  • TREATMENT OF FRAGILE X SYDROME WITH CANNABIDIOL
    Publication number: 20200360299
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • Treatment of fragile x syndrome with cannabidiol
    Patent number: 10758497
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: September 1, 2020
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree